NATR — Nature's Sunshine Products, Inc. · 2026-09-07 · Verdict: WATCH · Conviction 3

Price $14.02 (screen row in universe_under2b.csv dated 2026-09-07; no live prices available) · Mkt cap $247M · EV $164M · EV/EBIT 5.6x LTM · EV/FY26E adj EBITDA 3.3x · FCF yield 7.3% on cap, 11.0% on EV (LTM) · Net cash $82.5M · ADV $3.3M Sources read: 10-K 2026-03-10 (Items 1, 1A, 7), 10-Q 2026-08-06, DEF 14A 2026-03-27, four 8-Ks (2026-03-10 to 2026-08-06), Form 4s (12m). No transcript or prepared remarks were filed, so section 5 rests on written guidance, not Q&A.

1. What the business actually does

Nature's Sunshine makes herbal and nutritional supplements, mostly at its own Spanish Fork, Utah plant, and sells them in more than 40 countries through independent consultants (10-K 2026, Item 1). 2025 segments: Asia $221.8M, North America $143.6M, Europe $93.1M, Latin America $21.6M (10-K 2026, Item 7). About 72.2 percent of sales are outside the US (10-K 2026, Item 1A), so translation is a first-order driver.

2. Why it is mispriced — the edge case

There is no clean edge case, and that decides the verdict. The stock is 49.6 percent off its high and down 44.1 percent in six months, yet 12-1 momentum is still positive (screen row): a round trip, not forced selling. Shares roughly doubled on the 2025 turnaround (adjusted EBITDA up 21.7 percent, 8-K 2026-03-10) then gave it all back after the August guidance cut.

What is genuinely divergent: H1 2026 adjusted EBITDA rose 16.5 percent to $25.9M (8-K 2026-08-06) while market value halved. Two value funds hold 24 percent, Wynnefield 14.1 and Prescott 10.2 (DEF 14A 2026), and Prescott added 161,389 shares in August at $14.69 to $16.75, at or above today's price (Form 4s, 2026-08-10, 2026-08-19), one holder averaging down. At $3.3M of volume the name is under-followed, but under-followed is not misunderstood.

3. Unit economics and growth

The operating improvement is real. Gross margin went 71.5 percent (2024) to 72.4 percent (2025) to 73.7 percent in Q2 2026, up 194 basis points year over year (10-K 2026, Item 7; 8-K 2026-08-06), and H1 operating income rose 43.8 percent to $15.0M on 5.2 percent sales growth (10-Q 2026-08-06).

The trend inside H1 is the problem. Constant-currency growth decelerated from about 6.9 percent in Q1 to 3.8 percent in Q2, and adjusted EBITDA went from up 32.9 percent in Q1 to flat in Q2 at $11.3M. Japan grew 50.7 percent in local currency but Taiwan fell 15.6 percent and China 20.1 percent, while North American digital sales grew 26 percent (10-Q and 8-K 2026-08-06). No consultant or customer counts appear in the filings, so sales-force productivity cannot be verified.

Cash conversion is the weak point. H1 operating activities used $1.0M against $6.9M a year earlier (10-Q 2026-08-06): receivables rose 61 percent to $13.9M, deferred revenue fell $3.8M, accrued liabilities $8.4M. Part is seasonal, since FY25 produced $35.3M of operating cash flow off only $6.9M in H1 2025, but conversion still worsened $8.0M year over year while adjusted EBITDA improved $3.7M. LTM free cash flow is about $18.1M versus FY25's $28.8M, with H1 capex up to $5.3M.

4. Balance sheet and capital allocation

$82.5M cash, zero debt and a $25.0M undrawn revolver to July 2027 (10-Q 2026-08-06), which resolves the screen's "debt data missing" warning in the company's favour. Location matters: only $15.7M is in the US, $66.8M offshore subject to withholding taxes and repatriation restrictions, so usable net cash is well under 34 percent of market value.

Buyback discipline went backwards: 1,260,000 shares at about $12.94 in FY25 (10-K 2026, Item 7) versus 113,000 at $22.55 in H1 2026, and share count rose from 17,508k to 17,614k as equity comp outpaced repurchases. Insiders own 3.1 percent and CEO Ken Romanzi owned zero shares at 2026-02-27 (DEF 14A 2026). Every management Form 4 in twelve months is a sale, at $19.90 to $21.84 in May and June; the only buyer is Prescott.

5. Management: what they said vs what they did

Guidance issued 2026-03-10 and reaffirmed 2026-05-07 was cut on 2026-08-06 to $490 to $500M of sales and $48 to $52M of adjusted EBITDA, from $500 to $515M and $50 to $54M, on the dollar and China. The new range is harder than it looks: against H1 adjusted EBITDA of $25.9M the midpoint implies H2 of about $24.1M versus $27.1M in H2 2025, down 11 percent, and even the high end implies a decline on roughly flat H2 sales. The gap is the Vision for Growth spending Romanzi began in Q2. CFO Shane Jones resigned effective 2026-06-05 (8-K 2026-05-11); Ruth Perkins, from Estée Lauder and PepsiCo, started 2026-09-01. BIS closed the trade-controls self-disclosure; OFAC remains pending (10-Q 2026-08-06).

6. Valuation

EV of $164.4M is 3.3x the $50M guided adjusted EBITDA midpoint, which flatters. Removing roughly $13.0M of D&A, $7.3M of share-based comp and $1.5M of other adjustments leaves about $28M of FY26 operating income, taxed at the 36.0 percent H1 rate because foreign tax credits carry a valuation allowance (10-Q 2026-08-06). NOPAT is about $18.3M, an 11.1 percent yield on EV, roughly 9x ex-cash earnings. Reverse DCF: at a 10 percent cost of capital the price implies after-tax operating profit shrinking about 1 percent a year in perpetuity.

Base (50 percent): FY26 at guide, FY27 EBITDA $52M as the spend annualises, 4.75x, net cash $90M, about $19. Bear (30 percent): China and Taiwan keep shrinking, FX stays adverse, the spend does not convert, FY27 EBITDA $42M at 3.5x, about $12.50. Bull (20 percent): Japan and digital hold, FX turns, FY27 EBITDA $58M at 6.0x, about $25. Probability-weighted $18.25, 30 percent above $14.02.

7. Catalysts and timeline

Q3 results in early November: the first read on H2 cash conversion, on whether growth reaccelerates off 3.8 percent, and Perkins's first quarter. Then the OFAC outcome and any buyback restarted near $14.

8. Risks and pre-registered kill criteria

1. Full-year 2026 operating cash flow below $25M (FY25 was $35.3M).
2. Constant-currency net sales growth below 2 percent for two consecutive quarters.
3. Asia segment net sales down year over year in constant currency in any quarter, meaning China and Taiwan have overwhelmed Japan.
4. Insider or 10 percent-holder net selling above $2M in any rolling six months.

9. Verdict and one-paragraph summary

WATCH, conviction 3. Nature's Sunshine is a debt-free supplement maker at $14.02 with $82.5M of cash, at 3.3x guided 2026 EBITDA after a 50 percent drawdown, with margins and operating income both improving. Three things stop it being an IDEA. The cheapness is largely an artifact of adjusted EBITDA: D&A, share-based comp and a 36 percent tax rate turn 3.3x into roughly 9x ex-cash earnings, and $66.8M of the cash is offshore. The profit is not converting, with H1 operating cash flow of negative $1.0M against positive $6.9M. And every point of the new guidance range implies H2 EBITDA below last year's, so the company is spending through a deceleration in which Q2 constant-currency growth fell from about 6.9 to 3.8 percent and China fell 20 percent. The Q3 print moves this to IDEA or PASS.

Research for discussion, not investment advice. Positions and sizing are the reader's decision.